n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Diabetes Mellitus, Type 1 in 5 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease believed to be caused by an inflammatory process in the pancreas leading to selective destruction of the beta cells." | 1.31 | COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. ( Floyd, RA; Jacob, JM; Kotake, Y; Tabatabaie, T; Waldon, AM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nacci, C | 1 |
| Tarquinio, M | 1 |
| De Benedictis, L | 1 |
| Mauro, A | 1 |
| Zigrino, A | 1 |
| Carratù, MR | 1 |
| Quon, MJ | 1 |
| Montagnani, M | 1 |
| Nasrallah, R | 1 |
| Robertson, SJ | 1 |
| Hébert, RL | 1 |
| Tabatabaie, T | 2 |
| Vasquez-Weldon, A | 1 |
| Moore, DR | 1 |
| Kotake, Y | 2 |
| Litherland, SA | 1 |
| Xie, XT | 1 |
| Hutson, AD | 1 |
| Wasserfall, C | 1 |
| Whittaker, DS | 1 |
| She, JX | 1 |
| Hofig, A | 1 |
| Dennis, MA | 1 |
| Fuller, K | 1 |
| Cook, R | 1 |
| Schatz, D | 1 |
| Moldawer, LL | 1 |
| Clare-Salzler, MJ | 1 |
| Waldon, AM | 1 |
| Jacob, JM | 1 |
| Floyd, RA | 1 |
5 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experime | 2009 |
Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Body Weight; Creatinine; | 2009 |
Free radicals and the pathogenesis of type 1 diabetes: beta-cell cytokine-mediated free radical generation via cyclooxygenase-2.
Topics: Animals; Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibi | 2003 |
Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.
Topics: Adolescent; Adult; Aged; Alleles; Antigen-Presenting Cells; Autoantibodies; Case-Control Studies; Ch | 1999 |
COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice.
Topics: Animals; Blood Glucose; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Di | 2000 |